Lava Therapeutics N.V. (LVTX)

$1.42 -0.10 (-6.58%)
Market Cap 39.98M
Revenue (ttm) 11.98M
Net Income (ttm) -25.11M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -209.60%
Debt to Equity Ratio 0.18
Volume 38,900
Avg Vol 39,978
Day's Range N/A - N/A
Shares Out 26.31M
Stochastic %K 25%
Beta 0.48
Analysts Sell
Price Target $1.83

Company Profile

LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prosta...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 85 016 3100
Address:
Yalelaan 62, Utrecht, Netherlands
bambus3001
bambus3001 Jul. 25 at 3:31 PM
$LVTX hin und her und doch stabil !!
0 · Reply
bambus3001
bambus3001 Jul. 24 at 4:07 PM
$LVTX 1.nervöse Zuckungen kündigen grosses an!!
0 · Reply
bambus3001
bambus3001 Jul. 23 at 11:55 AM
$LVTX Heute vermute Ich Wird die Reise gen Nordpol weitergehen ??? Also Ich bin Positiv gestimmt.
0 · Reply
bambus3001
bambus3001 Jul. 14 at 7:59 PM
$LVTX so mag Ich es ,kleine Schritte und es ist noch fast keiner dabei .4 G Regel auch hier wie bei hrtx
0 · Reply
kshonstocks
kshonstocks Jul. 14 at 6:29 PM
$LVTX higher highs on the chart
0 · Reply
biochirp
biochirp Jul. 14 at 6:00 PM
$LVTX making a move again
0 · Reply
bambus3001
bambus3001 Jul. 8 at 4:43 PM
$LVTX very strong by
0 · Reply
DavidScott
DavidScott Jun. 16 at 3:41 AM
On watch tomorrow (swing trading) // Part 3 🔥📈📚 $LVTX $CLOV $FFAI $BBAI $INO
0 · Reply
DavidScott
DavidScott Jun. 2 at 3:15 AM
On watch tomorrow (swing trading) // Part 3 🔥📈📚 $SPRC $TOON $LVTX $PHUN $TROO
1 · Reply
JarvisFlow
JarvisFlow May. 15 at 2:07 PM
JMP Securities updates rating for LAVA Therapeutics ( $LVTX ) to Market Perform.
0 · Reply
Latest News on LVTX
LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

May 14, 2025, 7:30 AM EDT - 2 months ago

LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

Apr 16, 2025, 7:30 AM EDT - 3 months ago

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Mar 28, 2025, 7:30 AM EDT - 4 months ago

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang

Feb 28, 2025, 12:32 PM EST - 5 months ago

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

Jan 10, 2025, 8:23 AM EST - 7 months ago

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

Dec 10, 2024, 7:30 AM EST - 8 months ago

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 11 months ago

LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

LAVA Reports Second Quarter 2024 Financial Results and Business Update

Aug 20, 2024, 7:30 AM EDT - 1 year ago

LAVA Reports Second Quarter 2024 Financial Results and Business Update

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 20, 2024, 7:30 AM EDT - 1 year ago

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

LAVA Announces Annual Meeting of Shareholders

Jun 10, 2024, 7:00 AM EDT - 1 year ago

LAVA Announces Annual Meeting of Shareholders

LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 30, 2024, 7:00 AM EDT - 1 year ago

LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference

LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results

May 21, 2024, 7:00 AM EDT - 1 year ago

LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results

LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference

May 6, 2024, 4:05 PM EDT - 1 year ago

LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference

LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results

Mar 20, 2024, 7:00 AM EDT - 1 year ago

LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results

LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)

Mar 5, 2024, 7:30 AM EST - 1 year ago

LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)

LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®

Jan 25, 2024, 7:00 AM EST - 1 year ago

LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®

Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Nov 16, 2023, 7:00 AM EST - 1 year ago

Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 7:11 AM EDT - 2 years ago

LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Aug 22, 2023, 7:00 AM EDT - 2 years ago

LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference

Aug 14, 2023, 7:00 AM EDT - 2 years ago

LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference

LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway

Jun 14, 2023, 9:00 AM EDT - 2 years ago

LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway

LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

Jun 8, 2023, 7:00 AM EDT - 2 years ago

LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development

Jun 1, 2023, 4:20 PM EDT - 2 years ago

LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development

LAVA Therapeutics to Participate in the Jefferies Healthcare Conference

Jun 1, 2023, 8:09 AM EDT - 2 years ago

LAVA Therapeutics to Participate in the Jefferies Healthcare Conference

LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results

Apr 11, 2023, 7:00 AM EDT - 2 years ago

LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results

LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors

Mar 9, 2023, 8:05 AM EST - 2 years ago

LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors

LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium

Feb 16, 2023, 7:00 AM EST - 2 years ago

LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium

LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference

Feb 9, 2023, 7:00 AM EST - 2 years ago

LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference

LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

Feb 6, 2023, 7:00 AM EST - 2 years ago

LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium

Jan 23, 2023, 7:00 AM EST - 2 years ago

LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium

LAVA Therapeutics Announces Appointment of New Directors to the Board

Jan 6, 2023, 1:07 PM EST - 2 years ago

LAVA Therapeutics Announces Appointment of New Directors to the Board

LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jan 3, 2023, 7:00 AM EST - 2 years ago

LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

Dec 10, 2022, 10:00 AM EST - 2 years ago

LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results

Nov 16, 2022, 4:05 PM EST - 2 years ago

LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results

LAVA Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 3, 2022, 4:05 PM EDT - 2 years ago

LAVA Therapeutics to Present at the Jefferies London Healthcare Conference

LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 3, 2022, 9:00 AM EDT - 2 years ago

LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer

Nov 1, 2022, 7:00 AM EDT - 2 years ago

LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer

LAVA Therapeutics: Assessing A Promising Innovator

Oct 18, 2022, 2:32 AM EDT - 3 years ago

LAVA Therapeutics: Assessing A Promising Innovator

LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Oct 7, 2022, 11:00 AM EDT - 3 years ago

LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

Sep 26, 2022, 8:00 AM EDT - 3 years ago

Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

LAVA Therapeutics Provides Business Update and Reports Second Quarter Financial Results

Sep 13, 2022, 4:05 PM EDT - 3 years ago

LAVA Therapeutics Provides Business Update and Reports Second Quarter Financial Results

LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Sep 7, 2022, 7:41 AM EDT - 3 years ago

LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients

Jun 16, 2022, 4:05 PM EDT - 3 years ago

LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients

LAVA Therapeutics Announces Two Appointments to its Board of Directors

Jun 15, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics Announces Two Appointments to its Board of Directors

LAVA Therapeutics to Participate at the Jefferies Healthcare Conference

Jun 2, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics to Participate at the Jefferies Healthcare Conference

LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 1, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

LAVA Therapeutics Announces Annual Meeting of Shareholders

May 31, 2022, 4:05 PM EDT - 3 years ago

LAVA Therapeutics Announces Annual Meeting of Shareholders

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

May 17, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies

May 12, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies

LAVA Therapeutics to Participate at the UBS Global Healthcare Conference

May 5, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics to Participate at the UBS Global Healthcare Conference

bambus3001
bambus3001 Jul. 25 at 3:31 PM
$LVTX hin und her und doch stabil !!
0 · Reply
bambus3001
bambus3001 Jul. 24 at 4:07 PM
$LVTX 1.nervöse Zuckungen kündigen grosses an!!
0 · Reply
bambus3001
bambus3001 Jul. 23 at 11:55 AM
$LVTX Heute vermute Ich Wird die Reise gen Nordpol weitergehen ??? Also Ich bin Positiv gestimmt.
0 · Reply
bambus3001
bambus3001 Jul. 14 at 7:59 PM
$LVTX so mag Ich es ,kleine Schritte und es ist noch fast keiner dabei .4 G Regel auch hier wie bei hrtx
0 · Reply
kshonstocks
kshonstocks Jul. 14 at 6:29 PM
$LVTX higher highs on the chart
0 · Reply
biochirp
biochirp Jul. 14 at 6:00 PM
$LVTX making a move again
0 · Reply
bambus3001
bambus3001 Jul. 8 at 4:43 PM
$LVTX very strong by
0 · Reply
DavidScott
DavidScott Jun. 16 at 3:41 AM
On watch tomorrow (swing trading) // Part 3 🔥📈📚 $LVTX $CLOV $FFAI $BBAI $INO
0 · Reply
DavidScott
DavidScott Jun. 2 at 3:15 AM
On watch tomorrow (swing trading) // Part 3 🔥📈📚 $SPRC $TOON $LVTX $PHUN $TROO
1 · Reply
JarvisFlow
JarvisFlow May. 15 at 2:07 PM
JMP Securities updates rating for LAVA Therapeutics ( $LVTX ) to Market Perform.
0 · Reply
MoonDT2024
MoonDT2024 Apr. 21 at 12:55 PM
$FUBO $GME $LVTX $PHUN $NNDM
0 · Reply
mbhatti1981
mbhatti1981 Apr. 21 at 6:29 AM
$FUBO $GME $LVTX $NNDM $PHUN
0 · Reply
DavidScott
DavidScott Apr. 21 at 3:01 AM
On watch tomorrow (swing trading) // Part 3 🔥📈📚 $FUBO $GME $LVTX $PHUN $NNDM
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Apr. 17 at 10:23 AM
WATCHLIST APR 17 2025. $LYFT Lyft Announced It Has Entered Into A Definitive Agreement To Acquire Freenow From BMW Group And Mercedes-benz Mobility For Approximately €175M Or $197M In Cash $DATS DatChat Receives Notice Of Allowance For European Patent Application For Advanced Digital Privacy Technology Titled "Systems And Methods Of Transforming Electronic Content." $TGL Treasure Global Forms Exclusive Strategic Partnership With Mezzofy To Become Sole Distributor Of Its Digital Coupon Platform In Malaysia, Targeting $2M–$4M In Recurring Annual Revenue Within 12 Months $BAC Argus Research Maintains Buy on Bank of America, Lowers Price Target to $47 $LVTX LAVA Therapeutics shares are trading higher after the company announced it received a $5.1 million payment obligation waiver.
2 · Reply
DavidScott
DavidScott Apr. 17 at 3:33 AM
On watch tomorrow (swing trading) // Part 2 🔥📈📚 $HOLO $WWR $LVTX $GEVO $ACB
0 · Reply
DavidScott
DavidScott Apr. 16 at 8:06 PM
$SBEV $HOLO $LVTX $WWR $MIRA = Awesome work everyone! We taught those bears a valuable lesson today. These were our main trades this session! We are looking for more momentum on these names again going into Thursday. If you need any guidance or a mentor, then feel free to message me anytime! ✅🙌 Have a great day everybody! 🎉
1 · Reply
DavidScott
DavidScott Apr. 7 at 4:37 AM
On watch tomorrow (swing trading) // Part 3 🔥📈📚 $SIDU $NNDM $CLOV $FFAI $LVTX
0 · Reply
JarvisFlow
JarvisFlow Mar. 31 at 11:00 AM
HC Wainwright & Co. updates rating for LAVA Therapeutics ( $LVTX ) to Neutral, target set at 1.5.
0 · Reply
DavidScott
DavidScott Mar. 31 at 4:16 AM
On watch tomorrow (swing trading) // Part 3 🔥📈📚 $INO $NNDM $LUNR $CLOV $LVTX
0 · Reply
hitmongreen
hitmongreen Mar. 28 at 2:37 PM
$LVTX 🤔
0 · Reply
DonCorleone77
DonCorleone77 Mar. 28 at 11:42 AM
$LVTX Lava Therapeutics expects $1M of expenses related to restructuring plan In February 2025, the Company adopted a restructuring plan to extend its capital resources in connection with initiating a process to evaluate strategic alternatives. As part of the restructuring plan, the Company's board of directors approved a reduction of approximately 30% of the Company's global workforce to better align resources with the Company's focus on the evaluation of strategic options and the Phase 1 study for LAVA-1266. The Company expects approximately $1.0 million of expenses related to the restructuring to be incurred during the six months ended June 30, 2025, of which approximately $0.3 million of cash payments are expected to be made during 2025.
0 · Reply
DonCorleone77
DonCorleone77 Mar. 28 at 11:37 AM
$LVTX Lava Therapeutics sees cash runway into 2027 As of December 31, 2024, LAVA had cash, cash equivalents, and investments of $76.6 million, compared to cash, cash equivalents, and investments of $95.6 million as of December 31, 2023. The Company believes its current cash, cash equivalents and investments will be sufficient to fund operations into 2027.
0 · Reply